Notably, RHAMM-targeted peptide vaccines have shown the ability to elicit potent, specific CD8+ T-cell responses and demonstrate efficacy in hematologic cancers, suggesting their applicability in broader cancer immunotherapy. The gene discussed is CD8A; the disease is hematopoietic and lymphoid cell neoplasm.